CN1182864C - Medicine for vascular denmentia disease and preparation method - Google Patents
Medicine for vascular denmentia disease and preparation method Download PDFInfo
- Publication number
- CN1182864C CN1182864C CNB031119646A CN03111964A CN1182864C CN 1182864 C CN1182864 C CN 1182864C CN B031119646 A CNB031119646 A CN B031119646A CN 03111964 A CN03111964 A CN 03111964A CN 1182864 C CN1182864 C CN 1182864C
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- add
- preparation
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention belongs to a pure traditional Chinese medicine preparation for treating vascular denmentia and a preparation method thereof. The preparation is prepared from the following raw materials according to the weight proportions: 500 to 800 g of chuanxiong rhizome, 500 to 800 g of epimedium herb, 300 to 450 g of ginkgo leaf and 300 to 450 g of angelica. The preparing method comprises: ethanol extraction: the epimedium herb and the ginkgo leaf; extraction of the medicine of volatile oil: the chuanxiong rhizome and the angelica; the extraction of medicine with a decocting method: the medicine dregs of the chuanxiong rhizome and the angelica after the volatile oil is extracted. The preparation has the effects for activating blood circulation to dissipate blood stasis, invigorating the kidney and benefiting intelligence, and is used for treating vascular dementia and people with blocked brain and nerves and weak kidney qi. The medicine and the preparation method thereof have the advantages of favorable effect, little medicine smell, high biological availability, advanced technology, accurate treating effect, safety and reliability. The preparation method has the advantages of high extraction efficiency, high purity and less medicine effect loss, and is suitable for modern industrial production.
Description
(1) technical field
The invention belongs to a kind of medicine for the treatment of the vascular dementia disease and preparation method thereof, particularly a kind of pure Chinese medicinal preparation for the treatment of the vascular dementia disease and preparation method thereof.
(2) background technology
Vascular dementia (VD) is the acquired cognitive impairment syndrome that the cerebrovascular disease by different reasons, pathology causes, and is modal a kind of in China's senile dementia, accounts for 68.2% of senile dementia sum.At present, because of suffering from the number of senile dementia death, become the 4th cause of death after heart disease, tumor and apoplexy.Therefore, the research of this disease is still all attached great importance in China in western countries.The prevention of vascular dementia and treatment, doctor trained in Western medicine mainly are to adopt to improve cerebral metabolism medicine and cerebral vasodilator, cooperate rehabilitation, though certain therapeutic effect is arranged, can not eradicate vascular dementia.
(3) summary of the invention
The object of the present invention is to provide a kind of evident in efficacy, the medicine of the treatment vascular dementia disease of the pure Chinese medicinal preparation of few side effects.
Another object of the present invention is to provide a kind of dna purity height, and the ingredient loss is few, is suitable for the preparation method that modern industrialization is produced.
Medicine disclosed by the invention is the capsule of being made by the raw material of following weight component,
Rhizoma Chuanxiong 500-800g Herba Epimedii 500-800g
Folium Ginkgo 300-450g Radix Angelicae Sinensis 300-450g.
Medicine of the present invention, its better raw material weight component is:
Rhizoma Chuanxiong 580-680g Herba Epimedii 580-680g
Folium Ginkgo 340-420g Radix Angelicae Sinensis 340-420g
Medicine of the present invention, its best raw material weight component is:
Rhizoma Chuanxiong 600g Herba Epimedii 650g
Folium Ginkgo 350g Radix Angelicae Sinensis 380g
Medicine of the present invention is to carry out as follows,
(1) Radix Angelicae Sinensis, Rhizoma Chuanxiong power are broken into coarse powder, add the water of 7 times of amounts, and steam distillation extracts volatile oil and carried most to volatile oil in 4 hours; Aqueous solution behind the extraction volatile oil is put in addition; Medicinal residues decoct with water secondary, add the water of 10 times of weight for the first time, add the water of 8 times of amounts for the second time, each 1 hour, collecting decoction, the aqueous solution merging with behind the extraction volatile oil is concentrated under 55 ℃, relative density is 1.05-1.08, room temperature to be chilled to adds ethanol and makes that to contain alcohol amount be 70%, leaves standstill, filter, alcoholic solution is standby;
(2) the sheep leaves of pulse plants, Folium Ginkgo add 70% alcohol heating reflux extraction 2 times, add the solvent of 12 times of weight for the first time, add the solvent of 8 times of amounts for the second time, extract 2 hours at every turn, merge extractive liquid, filters, and filtrate and above-mentioned alcoholic solution merge, and reclaims ethanol, concentrate, drying is ground into fine powder;
(3) get the cycloheptaamylose of 5 times of weight volatilization oil masses, add 20% ethanol of 2 times of amounts, grind to form pasty state, add the volatile oil that Rhizoma Chuanxiong, Radix Angelicae Sinensis extract, ground 2 hours, and be lower than 60 ℃ of dryings, pulverize, with above-mentioned fine powder mixing, add an amount of starch, mixing, encapsulated, promptly.
1. the research data of drug manufacture technology of the present invention
1.1 the selection of dosage form
This preparation is selected capsule for use, the reasons are as follows:
Medicine of the present invention is by decoction.Former daily prescription crude drug amount is 24g, and dosage is less, provides possibility for being made into capsule.(2) capsule, production technology is simple, and other dosage form also has good absorbing relatively, and produce effects is fast, the characteristics of good stability.(3) the alzheimer disease course of disease is long, capsule have carry, the characteristics of taking convenience, help patient's medication.So this preparation is selected capsule for use.
1.2. raw material
Rhizoma Chuanxiong: the decoction pieces that is cut into for the dry rhizome of samphire Rhizoma Chuanxiong Ligustucum chuanxiong Hort.
Herba Epimedii: be the plant Herba Epimedii Epimedium brevicornum Marim of XIAONIE section dry aerial parts
Radix Angelicae Sinensis: be the tableted decoction pieces of dry root of umbelliferae angelica Anglica sinesis (Oliv.) Diels
Folium Ginkgo: be the dried leaves of Ginkgoaceae plant Ginkgo biloba Ginkgo biloba
1.3 the design of prescription analysis and extraction process
The Rhizoma Chuanxiong acrid in the mouth, warm in nature.Go into liver, gallbladder, pericardium channel.The special blood-activating and qi-promoting of merit.So the energy blood circulation promoting and blood stasis dispelling, logical brain network.The brain ruton, brains must be supported, and the refreshment Fructus Alpiniae Oxyphyllae is monarch drug in the side.The hot temperature of Radix Angelicae Sinensis nature and flavor sweetness and bitterness is gone into the conscience spleen channel.The sweet benefit of this product is hot looses, and it is logical that hardship is let out temperature, and property softens and moistens.Hot using warming therapy can help the Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling, and the property of sweet benefit can make QI and blood fill Sheng, and blood is contained the then smooth no stasis of blood, and lubricant nature can prevent that the suffering of Rhizoma Chuanxiong is dry.The Folium Ginkgo nature and flavor are sweet, bitter, puckery flat.Go into the heart, spleen, lung meridian.Have promoting blood circulation and stopping pain, the beneficial heart is astringed the lung, the merit of removing dampness pain relieving.With the same usefulness of Radix Angelicae Sinensis, principal drug assistance Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling brain network, beneficial mind is ministerial drug in the side altogether.Herba Epimedii nature and flavor suffering, sweet, warm.Go into the Liver and kidney warp.The special reinforcing the kidney and supporting YANG of merit.Good merchantable brand for invigorating kidney, promoting blood circulation benefit will is adjuvant drug in the side.More than all medicine mutually 5, blood circulation promoting and blood stasis dispelling is played in through-supplementation altogether, the merit of the kidney invigorating Fructus Alpiniae Oxyphyllae.
Rhizoma Chuanxiong has the effect of blood-activating and qi-promoting.Significantly the cerebral blood flow increasing amount reduces cerebral vascular resistance.Rhizoma Chuanxiong and the ligustrazine that is contained can alleviate cerebral anoxia, the bilateral ligation carotid artery that KCN causes and cause the rat due to the cerebral ischemia, the brain tissue impairment of mice and the rising of lipid peroxide.The active component of Rhizoma Chuanxiong comprises volatile oil, alkaloid and ferulic acid, and the extraction of a Rhizoma Chuanxiong should adopt steam distillation to extract volatile oil, because of ligustrazine and ferulic acid all can be dissolved in hot water, so the Rhizoma Chuanxiong medicinal residues that extract behind the volatile oil should adopt the decocting method extraction.
Radix Angelicae Sinensis has the effect of enriching blood and invigorating blood circulation.Volatile oil that is contained and ferulic acid can significantly increase peripheral vascular blood flow, reduce vascular resistance.The rising that Radix Angelicae Sinensis pours into the cerebral tissue lipid peroxide after to cerebral anoxia, ischemia again has the obvious suppression effect.Ferulic acid is a kind of antioxidant, and the hydrogen peroxide that rat liver mitochondria is generated reduces 62%.Therefore Radix Angelicae Sinensis should adopt steam distillation to extract volatile oil, decocting method extracts ferulic acid.
Herba Epimedii has the effect of invigorating kidney, promoting blood circulation.The DNA that the extract of Herba Epimedii and the Herba Epimedii total flavones that is contained have tangible increase mice synthesizes, strengthens humoral immunization and the immunization of cell of mice.So the extraction of Herba Epimedii should be to extract the Herba Epimedii total flavones that it contains.The dissolubility of Herba Epimedii total flavones in ethanol is greater than the dissolubility in water, so Herba Epimedii should adopt ethanol extraction.
Folium Ginkgo has the effect of blood circulation promoting and blood stasis dispelling.The total flavones that extracts from Folium Ginkgo, bilobalide have the effect of blood vessel dilating preferably, improve the nutrition of brain.So the extraction of Folium Ginkgo also should be to extract its flavone that is contained and lactone compound.And the dissolubility of this compounds in ethanol is greater than the dissolubility in water, so Folium Ginkgo should adopt ethanol extraction.
According to above data, in conjunction with the characteristics of this preparation, the extraction process of this preparation can design as follows:
The medicine of ethanol extraction: Herba Epimedii, Folium Ginkgo.
Extract the medicine of volatile oil: Rhizoma Chuanxiong, Radix Angelicae Sinensis.
The medicine that decocting method extracts: Rhizoma Chuanxiong, Radix Angelicae Sinensis medicinal residues behind the extraction volatile oil.
2. the pharmacological toxicology research data of medicine of the present invention is summarized
2.1 medicine of the present invention cures mainly relevant main pharmacodynamics research with function
2.1.1. test objective
Medicine of the present invention, Main Ingredients and Appearance: Rhizoma Chuanxiong, Radix Angelicae Sinensis, Folium Ginkgo, Herba Epimedii.Effect: blood circulation promoting and blood stasis dispelling, the kidney invigorating Fructus Alpiniae Oxyphyllae.Be used for the treatment of vascular dementia.Blood stagnant in cerebral venation syndrome, deficiency of kidney-QI weak person.The symptom dull expression, bradykinesia, the hypophrenia, language is put upside down, and is forgetful, and it is poor to understand computing power, has a dizzy spell or tinnitus, and numb limbs and tense tendons is unsuccessful, and complexion secretly stagnates, and confusingly sleeps less, and tongue is dark red or purpura, stringy and thready pulse or deep and slow and puckery arranged.With reference to the main pharmacodynamics research requirement relevant of relevant new Chinese medicine with function, observe medicine of the present invention to the dementia rats learning and memory due to the cerebral ischemia reperfusion injury, monoamine neurotransmitter in the brain, superoxide dismutase, the Radical Metabolism thing, nitric oxide and brain morphology change, medicine of the present invention is to Dementia with Multiple Brain Infarction learning and memory in rats due to the paraffin oil, brain morphology changes, hemorheological change, medicine of the present invention is to the influence to the drug-induced loss of memory of the influence of brain microcirculation and medicine of the present invention, and medicine of the present invention is to the normal pressure hypoxia endurance test of mice.
2.2. test material
2.2.1 experimental animal: Wistar rat, body weight 240-300g.Kunming mouse, body weight 18-22g.
2.2.2 trial drug: each 4 of consumption of adult (every 0.5 gram is with respect to crude drug 2 grams), every days three times (24g/day, 0.343g/kg/ days, 70kg individuality).Mice is by three dosage gastric infusions, high dose: 6.4g/kg (crude drug), middle dosage 3.2g/kg, low dosage 1.6g/kg.(be equivalent to respectively be grown up consumption 18.7 times, 9.3 times, 4.7 times) with distilled water be mixed with drug level 64g/dl of the present invention, 32g/dl, 16g/dl (crude drug) are standby.Give the 0.1ml/10g body weight during medication.Rat is also by high, medium and low three dosage gastric infusions, and dosage is respectively: high dose 5.6g crude drug/kg (crude drug), middle dosage 2.8/kg, low dosage 1.4g/kg (be equivalent to respectively be grown up consumption 16.4 times, 8.2 times, 4.1 times).With distilled water be mixed with drug level 56g/dl of the present invention, 28g/dl, 14g/dl are standby.Medication gives 1ml/100g body weight.YINKELUO PIAN, every 40mg (containing Semen Ginkgo total flavones 9.6mg/ sheet), Shenzhen sea king's Pharmaceutical Co., Ltd produces lot number: 20020615, adult's (70kg) consumption 3.43mg/kg, rat is by 24mg/kg gastric infusion (be equivalent to be grown up consumption 7 times).Be mixed with 0.24% solution with distilled water, gastric infusion gives the 1ml/100g body weight during medication.Mice is pressed 30ml/kg, is mixed with 0.3mg% solution with distilled water, and gastric infusion gives the 0.1ml/10g body weight during medication.
2.3 result of the test
2.3.1 medicine of the present invention is to the influence of dementia rats due to the cerebral ischemia reperfusion injury
(1) to the influence of learning and memory
Medicine of the present invention influences result of the test to the dementia rats learning and memory due to the cerebral ischemia reperfusion injury and shows, after two weeks of medication, vascular dementia rats is kept away dark test incubation period, medicine high dose group of the present invention, middle dosage group, low dose group and Ginkgo Biloba Leaf Preparation group prolong, and compare difference tool significance with model control group.Average 3 minutes errors number, except that medicine low dose group of the present invention, each medication group and normal control group all reduce than model group, difference tool significance.The step down test result shows, after two weeks of medication, step down test incubation period, medicine high dose group of the present invention and the prolongation of Ginkgo Biloba Leaf Preparation group are compared the significance of difference with model control group.Average 5 minutes errors number, each medication group and normal control group all reduce than model group.Medicine of the present invention prolongs step down test incubation period, reduce errors number presents certain dose-effect relationship.
Morris water maze laboratory result shows, the orientation navigation result of the test shows, platform search time (escape latency, escape latercy) each medication group of medicine of the present invention and Ginkgo Biloba Leaf Preparation group all shorten than model group, go into the horizontal stand search time with the southern side quadrant and shorten the most obviously (P＜0.05).Space exploration test (spatial probe) shows, swim in swimming time, the platform quadrant in the ratio of swimming distance and total swimming distance, the platform quadrant in swimming distance, the platform quadrant in the platform quadrant swimming time and total time in outer swimming time, the platform quadrant ratio, pass through the platform number of times, each medication group is compared with model group all has significant difference.In always swim distance, average swimming rate of dosage group fast, compare difference tool significance with other each groups.In the quadrant in the swimming rate dosage group faster than high dose group, difference tool significance.Above result shows that medicine of the present invention has the obvious dementia rats learning and memory function that improves due to the cerebral ischemia reperfusion injury.
(2) to acetylcholine esterase, superoxide dismutase, Radical Metabolism product, nitric oxide production influence in the brain
Superization thing dismutase (SOD) was starkly lower than the normal control group still apparently higher than the normal control group three weeks after Radical Metabolism product malonaldehyde (MDA) medication in the vascular dementia rats brain due to the cerebral ischemia reperfusion damage.Medicine high dose group of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, malonaldehyde (MDA) reduces in the brain, superoxide dismutase (SOD) increased activity is compared difference tool significance (P＜0.05) with model control group.In addition, medicine high dose group of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, nitric oxide increases to some extent, acetylcholine esterase reduces to some extent, compares difference with the vascular dementia model group and does not have significance.Illustrate that medicine of the present invention has the increase superoxide dismutase, reduce free-radical generating, thus the damage that alleviates brain tissue cell.
(3) to the influence of cerebral morphology
Experimental result shows, each vascular dementia rats model group brain coefficient, normal matched group lowers (P＞0.05), medicine high dose group of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, the brain coefficient is a little more than model control group, but difference does not have significance (P＞0.05).
Cerebral morphology under the light microscopic changes demonstration, and obvious impairment appears in vascular dementia model group brain tissue cell, and obvious increase (P＜0.05) is compared in scoring with the normal control group.The high agent group of medicine of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, brain tissue cell damage scoring is lower than model control group, but difference does not have significance.Illustrate that medicine of the present invention is not obvious to the morphological change influence of vascular dementia model group brain tissue cell.
2.3.2 medicine of the present invention is to the influence of the dementia rats due to the paraffin oil thromboembolism
(1) to the influence of learning and memory
The step down test result shows, after two weeks of medication, vascular dementia rats step down test incubation period, medicine high dose group of the present invention, Ginkgo Biloba Leaf Preparation group and normal control group obviously prolong, and compare difference tool significance with model control group.Average 3 minutes errors number, each group does not all have significant difference with model group.Keep away dark result of the test and show, after two weeks of medication, vascular dementia rats is kept away dark test incubation period, and difference tool significance is compared in each dosage group of medicine of the present invention and the prolongation of Ginkgo Biloba Leaf Preparation group with model control group.Average 3 minutes errors number, each medication group and normal control group all reduce than model group, and difference does not have significance.
Morris water maze orientation navigation result of the test shows, platform search time (escape latency, escapelatercy) medicine of the present invention is to the medication group, and the Ginkgo Biloba Leaf Preparation group all shortens than model group, go into the horizontal stand search time with the southern side quadrant and say short the most obviously (P＜0.05), all the other all quadrants differences do not have significance.Space exploration test (spatialprobe) shows, swim in swimming time, the platform quadrant in the ratio of swimming distance and total swimming distance, the platform quadrant in swimming distance, the platform quadrant in the platform quadrant swimming time and total time in outer swimming time, the platform quadrant ratio, pass through the platform number of times, each medication group is compared with model group all has significant difference.Illustrate that medicine of the present invention has the tangible effect that improves learning and memory.
(2) to the influence of cerebral morphology
Experimental result shows, each vascular dementia rats model group brain coefficient, normal matched group lowers (P＞0.05), the high agent group of medicine of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, the brain coefficient is a little more than model control group, but difference does not have significance (P＞0.05).Cerebral morphology under the light microscopic changes demonstration, and obvious impairment appears in vascular dementia model group brain tissue cell, and obvious increase (P＜0.05) is compared in scoring with the normal control group.The high agent group of medicine of the present invention, middle dosage group, low dose group and after three weeks of Ginkgo Biloba Leaf Preparation group medication, brain tissue cell damage scoring is lower than model control group, but difference does not have significance.Illustrate that medicine of the present invention is not obvious to the morphological change influence of vascular dementia model group cerebral tissue.
(3) to the influence of hemorheology index
Result of the test shows, compares with the normal control group in each shear rate whole blood viscosity model group, all obviously raises.The tool significance.Under the medicine high dose group 1-180 shear rate of the present invention, whole blood viscosity medication group all obviously lowers, and compares difference tool significance with model control group.Under the 30-180 shear rate, dosage group whole blood viscosity obviously lowers in the medicine of the present invention; And under the high shear rate of 120-180, medicine low dose group whole blood viscosity of the present invention obviously lowers; Show that medicine of the present invention reduces whole blood viscosity and has certain dose-effect relationship.Illustrate that medicine of the present invention can obviously improve whole blood viscosity.
2.3.3 medicine of the present invention is to the influence of brain microcirculation
Result of the test shows that each medication group of medicine of the present invention and Ginkgo Biloba Leaf Preparation group medication hindbrain microcirculatory blood flow all obviously raise, wherein 40min after the high dose group administration.Begin to raise, 60, during 80min, still than increasing before the medication, and compare difference tool significance before the administration.In after the medication of dosage group 60, during 80min, after the low dose group medication during 60min, increase than medication forebrain microcirculatory blood flow, and compare difference tool significance before the administration.When Ginkgo Biloba Leaf Preparation group 40,60,80min, increase, and compare difference tool significance before the administration than medication forebrain microcirculation blood flow.After the high dose group administration 40,60,80,100min; Middle dosage group 60,80,100min; Low dose group 60,80min; Difference before value added before Ginkgo Biloba Leaf Preparation group 60,80,100min and the medication and matched group and the medication compares, difference tool significance.Each medication group of medicine of the present invention and Ginkgo Biloba Leaf Preparation group are than no significant difference.Show that medicine of the present invention has the effect of certain increase pia mater encephali microcirculatory blood flow.
2.3.4 medicine of the present invention is to the amnemonic influence of drug-induced
Result of the test shows that each medication group of medicine of the present invention and Ginkgo Biloba Leaf Preparation group step down test prolong to some extent than matched group incubation period, compare difference with matched group and do not have significance.Average 3 minutes errors number, except that medicine low dose group of the present invention, each medication group and normal control group all reduce than model group, difference tool significance.It is certain for amnemonic effect due to the anti-nitrous brain to show that medicine of the present invention has.
2.3.5 medicine of the present invention is to the test of the normal pressure anoxia enduring of mice
The result of the test of normal pressure anoxia enduring shows that the mice hypoxia endurance time under medicine high dose group of the present invention, the obvious normal pressure of Ginkgo Biloba Leaf Preparation group energy is compared with matched group, difference tool significance (P＜0.05).Dosage group in the medicine of the present invention, low dose group effect are not obvious.The improve normal pressure resisting oxygen lack of mice of medicine tool of the present invention is described.
Brief summary
Result of the test shows that medicine of the present invention obviously improves the dementia rats learning and memory due to the cerebral ischemia reperfusion injury; Lower radical metabolism product malonaldehyde (MDA) in the brain, strengthen superoxide dismutase (SOD) activity; But the morphological change influence to vascular dementia model group brain tissue cell is not obvious.Medicine of the present invention shows that to the influence of the dementia rats due to the paraffin oil thromboembolism medicine of the present invention can obviously improve the dementia rats learning and memory function due to the paraffin oil thromboembolism, reduces whole blood viscosity.Medicine of the present invention still can increase the brain microcirculation blood flow, improves the drug-induced dysmnesia, and can improve the normal pressure hypoxia-bearing capability of mice.
3. medicine acute toxicity test of the present invention
Medicine mice ig maximum dosage-feeding of the present invention is 224g/kg.Maximum dosage-feeding is equivalent to 653 times of clinical consumptions.Observed 7 days behind the mouse stomach, do not see death and other abnormal phenomenas, body weight gain is normal, and appetite is good.Put to death after 7 days, the ANOMALOUS VARIATIONS of internal organs is not seen in perusal yet, and the overt toxicity reaction does not appear in mice, and it is safe pointing out clinical use.
4. medicine long term toxicity test of the present invention
4.1 test method
This experimental observation 26 weeks of medicine continuous use of the present invention, the long term toxicity reaction of rat.Get 160 of health rats in 5 age in week, ♀ ♂ half and half is divided into matched group, low amount group, middle dosage group, high dose group at random.Every treated animal gastric infusion, 6 days weekly, continuous 26 weeks.Administration finishes the back and continues to observe for 4 weeks.Every day, the general behavior of observation experiment animal showed, the appetite body weight of record animal.In 13 weeks of medication, 26 weeks and 30 when week blood drawings detect the hematology, blood biochemical is learned index, and in medication during 13 weeks every group put to death 10 animals at random, when 26 weeks, put to death 20 animals at random for every group, 30 weeks were put to death the residue animals.Animal is cutd open inspection, and taking internal organ is weighed and is carried out histopathological examination.Route of administration adopts administration by gavage with clinical consistent, and every morning is administered once, and administration is 6 days weekly, adjusts dosage every 7 days according to the weight increase situation, and each group usefulness waits not isoconcentration administration of capacity.
4.2 result of the test
Continuous 26 weeks of gastric infusion of medicine 7g/kg of the present invention, animal general behavior, body weight gain, appetite, hematology, blood biochemical are learned, histopathologic examination does not see and the relevant toxic reaction of medicine medication of the present invention, except that part animal lungs occur being dispersed in the interstitial inflammation of distribution, every index is all no abnormal.
Continuous 26 weeks of gastric infusion of medicine 14g/kg of the present invention, animal general behavior, body weight gain, appetite, hematology, blood biochemical are learned, histopathologic examination does not see and the relevant toxic reaction of medicine medication of the present invention, except that part animal lungs occur being dispersed in the interstitial inflammation of distribution, every index is all no abnormal.
Medicine 28g/kg group of the present invention, continuously 26 weeks of gastric infusion, animal general behavior, appetite, hematology, blood biochemical are learned, histopathologic examination does not see, and the overt toxicity relevant with medicine medication of the present invention reacts.Remove part animal lungs and the interstitial inflammation of distribution and an animal occur being dispersed in because bladder and ureteral calculus death.The body weight gain of buck, no significant change.Body weight gain is slower than other each groups (P＞0.05) slightly during the jenny medication.
Conclusion: in 26 weeks of medicine continuous use of the present invention, the long term toxicity test result of rat shows that the toxic reaction dosage of medicine is greater than 28g/kg, and safe dose is less than 14g/kg.
5. Drug therapy vascular dementia stasis of blood resistance brain key of the present invention, deficiency of kidney-essence card clinical research summary
By at random, the clinical research of positive drug contrast (piracetam), observing vascular dementia altogether and belong to stasis of blood resistance brain key, deficiency of kidney-essence (blood stasis is suffered from a deficiency of the kidney) card patient 60 examples, is Shandong Chinese medicine Affiliated Hospital, Shandong Province Zibo City Hospital of Chinese Medicine and the outpatient of Hebei province Handan Municipality Traditional Chinese Medical Hospital.Be divided into test group 40 examples at random by the NDST2:1 table of random number, matched group 20 examples, dementia degree, sex distribution, mean age, the course of disease and the traditional Chinese medical science bed symptoms equal no significant difference that distributes has comparability before two groups of treatments.Two groups of period in a medicine are all stopped using other to the medicative medicine of dementia, and medication 2 months was 1 course of treatment.Test group clinic control 6 examples as a result, produce effects 10 examples, effective 16 examples, obvious effective rate is 40%, total effective rate reaches 77.5%; Matched group clinic control 1 example, produce effects 3 examples, effective 6 examples, obvious effective rate is 20%, and total effective rate reaches 50%, two group relatively, and the treatment group is better than matched group, P＜0.05.Studies show that simultaneously, medicine of the present invention is better than piracetam to the effect of improving of tcm symptom, especially soreness of the waist and knees, deafness and tinnitus, dribble of urine or incontinence, numb limbs and tense tendons, judgment go down, discernment goes down, computing power goes down etc. (P＜0.01, P＜0.05).For the evaluation that makes curative effect more accurate, have more objectivity, this research has selected all higher MMSE of sensitivity and specificity, HDS and FAQ scale to carry out the detection of neural psychology, cognitive competence in numerous similar scales, the result treats back HDS, FAQ and the MMSE integrated value all has improvement, but test group effect more obvious (P＜0.01), and test group MMSE integration is apparently higher than matched group (P＜0.05).Illustrate that medicine of the present invention is better than piracetam to the therapeutical effect of VD.To the effect of hemorheology, the every index in test group treatment back all is significantly improved (P＜0.01, P＜0.05), and equal no significant difference before and after the treatment of control group, visible medicine of the present invention has good function of promoting blood circulation to disperse blood clots.Do not find toxicity in the clinical research.Therefore we can say medicine of the present invention be safety non-toxic, determined curative effect the treatment vascular dementia the efficacious prescriptions medicine arranged.
The ground-breaking vascular dementia disease key that proposed of this research is stasis of blood resistance brain key, deficiency of kidney-essence; Set up the opinion that blood circulation promoting and blood stasis dispelling, the kidney invigorating Fructus Alpiniae Oxyphyllae combine and controlled thought, enriched the clinical research of the rationale of Chinese medicine vascular dementia, with domestic good with the technology comparative effectiveness, flavour of a drug are few, bioavailability is high, technology is advanced, determined curative effect, safe and reliable.
Therefore, medicine of the present invention has effectively, and flavour of a drug are few, bioavailability is high, technology is advanced, determined curative effect, safe and reliable.Preparation method has the extraction efficiency height, the purity height, and the drug effect loss is few, is suitable for modern industrialization production.
(4) specific embodiment
1. embodiment 1
Take by weighing raw material by following weight: Rhizoma Chuanxiong 500g, Herba Epimedii 800g, Folium Ginkgo 300g, Radix Angelicae Sinensis 450g.
(1) Radix Angelicae Sinensis, Rhizoma Chuanxiong power are broken into coarse powder, add the water of 7 times of amounts (weight), and steam distillation extracts volatile oil and carried most to volatile oil in 4 hours.Aqueous solution behind the extraction volatile oil is put in addition.Medicinal residues decoct with water secondary, the water that adds for the first time 10 times of amounts adds the water of 8 times of amounts, each 1 hour the second time, collecting decoction, merge with the aqueous solution behind the extraction volatile oil, being concentrated into relative density is 1.06 (55 ℃), room temperature to be chilled to, add ethanol and make that to contain alcohol amount be 70%, leave standstill, filter, alcoholic solution is standby.
(2) Herba Epimedii, Folium Ginkgo add 70% alcohol heating reflux extraction 2 times, add the solvent of 12 times of amounts (weight) for the first time, add the solvent of 8 times of amounts for the second time, extract 2 hours at every turn, merge extractive liquid, filters, and filtrate and above-mentioned alcoholic solution merge, and reclaims ethanol, concentrate, drying is ground into fine powder.
(3) get the cycloheptaamylose of 5 times of amounts (weight) volatilizations oil mass, add 20% ethanol of 2 times of amounts, grind to form pasty state, the volatile oil that adds Rhizoma Chuanxiong, Radix Angelicae Sinensis extraction, ground 2 hours, and be lower than 60 ℃ of dryings, pulverize, with above-mentioned extractum fine powder mixing, add an amount of starch, mixing, encapsulated, make 1000 of medicines of the present invention, promptly.
Usage and consumption: every day three times, each 5, boiled water is taken after mixing it with water
2. embodiment 2
Take by weighing raw material by following weight: Rhizoma Chuanxiong 800g, Herba Epimedii 500g, Folium Ginkgo 450g, Radix Angelicae Sinensis 300g.
Method for making is identical with embodiment 1 with usage.
3. embodiment 3
Take by weighing raw material by following weight: Rhizoma Chuanxiong 600g, Herba Epimedii 650g, Folium Ginkgo 350g, Radix Angelicae Sinensis 380g.
Method for making is identical with embodiment 1 with usage.
Claims (4)
1. medicine for the treatment of the vascular dementia disease is characterized in that: be the capsule of making by the raw material of following weight component,
Rhizoma Chuanxiong 500-800g Herba Epimedii 500-800g
Folium Ginkgo 300-450g Radix Angelicae Sinensis 300-450g.
2. according to the medicine of the described treatment vascular dementia of claim 1 disease, it is characterized in that: described raw material weight component is:
Rhizoma Chuanxiong 580-680g Herba Epimedii 580-680g
Folium Ginkgo 340-420g Radix Angelicae Sinensis 340-420g.
3. according to the medicine of claim 1 or 2 described treatment vascular dementia diseases, it is characterized in that: described raw material weight component is:
Rhizoma Chuanxiong 600g Herba Epimedii 650g
Folium Ginkgo 350g Radix Angelicae Sinensis 380g.
4. the preparation method of the medicine of treatment vascular dementia disease according to claim 1 is characterized in that: be to carry out as follows,
(1) Radix Angelicae Sinensis, Rhizoma Chuanxiong power are broken into coarse powder, add the water of 7 times of amounts, and steam distillation extracts volatile oil and carried most to volatile oil in 4 hours; Aqueous solution behind the extraction volatile oil is put in addition; Medicinal residues decoct with water secondary, add the water of 10 times of weight for the first time, add the water of 8 times of amounts for the second time, each 1 hour, collecting decoction, the aqueous solution merging with behind the extraction volatile oil is concentrated under 55 ℃, relative density is 1.05-1.08, room temperature to be chilled to adds ethanol and makes that to contain alcohol amount be 70%, leaves standstill, filter, alcoholic solution is standby;
(2) Herba Epimedii, Folium Ginkgo add 70% alcohol heating reflux extraction 2 times, add the solvent of 12 times of weight for the first time, add the solvent of 8 times of amounts for the second time, extract 2 hours at every turn, merge extractive liquid, filters, and filtrate and above-mentioned alcoholic solution merge, and reclaims ethanol, concentrate, drying is ground into fine powder;
(3) get the cycloheptaamylose of 5 times of weight volatilization oil masses, add 20% ethanol of 2 times of amounts, grind to form pasty state, add the volatile oil that Rhizoma Chuanxiong, Radix Angelicae Sinensis extract, ground 2 hours, and be lower than 60 ℃ of dryings, pulverize, with above-mentioned fine powder mixing, add an amount of starch, mixing, encapsulated, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031119646A CN1182864C (en) | 2003-03-14 | 2003-03-14 | Medicine for vascular denmentia disease and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031119646A CN1182864C (en) | 2003-03-14 | 2003-03-14 | Medicine for vascular denmentia disease and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1438005A CN1438005A (en) | 2003-08-27 |
| CN1182864C true CN1182864C (en) | 2005-01-05 |
Family
ID=27673995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031119646A Expired - Fee Related CN1182864C (en) | 2003-03-14 | 2003-03-14 | Medicine for vascular denmentia disease and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1182864C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101143181B (en) * | 2006-09-12 | 2010-11-03 | 广州中医药大学第二附属医院 | Traditional Chinese medicinal composition for treating senile dementia and preparation method and application thereof |
| CN101244127B (en) * | 2007-06-19 | 2010-12-29 | 湖南方盛制药股份有限公司 | Medicament for treating vascular dementia |
| CN102552365A (en) * | 2012-01-29 | 2012-07-11 | 迪沙药业集团有限公司 | Traditional Chinese medicine composition for treating vascular dementia |
| CN102614329A (en) * | 2012-04-16 | 2012-08-01 | 山东省中医药研究院 | Traditional Chinese medicine compound preparation for treating Alzheimer disease and preparation method thereof |
| CN103721102B (en) * | 2013-12-27 | 2017-06-23 | 南阳理工学院 | It is a kind of to treat Chinese patent drug of vascular dementia and preparation method thereof |
-
2003
- 2003-03-14 CN CNB031119646A patent/CN1182864C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1438005A (en) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN1840128A (en) | Medicine for treating cardiovascular disease | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN113995788B (en) | Liver protection composition and preparation process thereof | |
| CN110742972B (en) | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation | |
| CN101032580A (en) | Medicine for treating rheumatic diseases | |
| CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
| CN1182864C (en) | Medicine for vascular denmentia disease and preparation method | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN1263503C (en) | 'Changyuan' capsule and preparing techniue | |
| CN102258742A (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN101032604A (en) | Chinese medicine preparation for curing vascular type headache | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN1679698A (en) | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method | |
| CN101919924B (en) | Pharmaceutical composition for curing tristimania and preparation method and application thereof | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| WO2022016827A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050105 |